Lentivirus-Mediated RNAi Silencing of VEGF Inhibits Angiogenesis and Growth of Renal Cell Carcinoma in a Nude Mouse Xenograft Model
Authors:
- 1 December 2015
- journal article
- research article
- Published by SAGE Publications in DNA and Cell Biology
- Vol. 34 (12) , 717-727
Abstract
To construct and screen short hairpin RNA (shRNA) targeting vascular endothelial growth factor (VEGF), and investigate potential values of VEGF-shRNA on angiogenesis and growth in renal cell carcinoma (RCC) in a xenograft tumor model. VEGF-shRNA fragment was designed to connect plasmid vector, and RCC cells were transfected with shRNA. Real-time fluorescent quantitative polymerase chain reaction (RTFQ-PCR) was used to detect interference efficiency of VEGF gene. The xenograft tumor model was established in nude mice, and mice were randomly divided into blank control (BC) group, negative control (NC) group, and experimental group. RNA interference (RNAi) effect was detected by immunohistochemistry, and tumor volume changes were observed. Tumor-bearing nude mice model was established and mice were randomly divided into BC group, NC group, and treatment group. The tumor volume changes and tumor inhibition rate were recorded, and angiogenesis status was observed. The apoptosis of tumor cells and genetic toxicity of VEGF-shRNA were detected. VEGF-shRNA can inhibit VEGF mRNA expression with an inhibition ratio of 72.3%. Compared with NC group and BC group, experimental group presents smaller tumor volume, weight, and poor growth (all p < 0.05). Positive VEGF rate in experimental group is significantly lower than that in NC group and BC group (all p < 0.05). Significantly lower tumor volume, less microvessel density (MVD) value, and higher apoptotic index (AI) are found in treatment group compared with BC group and NC group (all p < 0.05). There was no significant difference in AI between treatment group and BC group regarding adjacent normal tissues (p > 0.05). VEGF plays an important role in the occurrence and development of RCC, chemical synthesis of VEGF small interfering RNA (siRNA) can specifically inhibit VEGF expression, angiogenesis and growth in RCC, and can promote cell apoptosis without genetic toxicity to normal tissues.Keywords
This publication has 32 references indexed in Scilit:
- Cycloamylose‐nanogel drug delivery system‐mediated intratumor silencing of the vascular endothelial growth factor regulates neovascularization in tumor microenvironmentCancer Science, 2014
- A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinomaCancer Treatment Reviews, 2014
- Optimal Management of Metastatic Renal Cell Carcinoma: Current StatusDrugs, 2013
- Renal cell carcinomaCancer Biomarkers, 2011
- Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trialsBJU International, 2011
- Targeted Therapy in the Treatment of Metastatic Renal Cell CancerOncology, 2009
- von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell CarcinomaJournal of Urology, 2008
- Angiogenesis as a therapeutic targetNature, 2005
- Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF)Journal of Cellular and Molecular Medicine, 2005
- Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cellsNature, 2001